Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis.
Plaque-type palmoplantar psoriasis (PPP) is associated with marked morbidity and frequently resistant to conventional therapies. Patients with long-standing plaque-type PPP failing previous treatments were included and treated with a 12-week intramuscular alefacept. The biweekly evaluation included hyperkeratosis, itching, and pain grading. In all of the seven treated patients significant to complete improvement in hyperkeratosis, pruritus and pain were observed, along with dose reduction or complete discontinuation of additional systemic treatments and without any recorded side effects. Alefacept should be considered as a therapeutic option for plaque-type PPP.
Lior
Sagi
S
Dermatology Day Care and Phototherapy Center, Sheba Medical Center, Tel Hashomer and Dermatology Clinic, Tel Nordau Medical Center, Tel Aviv, Israel. lior115@gmail.com
Grigory
Kriger
K
Pnina
Shemesh
S
Joseph
Shiri
S
Felix
Pavlotsky
P
D000328:Adult; D000368:Aged; D000077944:Alefacept; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007642:Keratosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept